New Evidence Available
Updated Recommendation
A new evidence synthesis was published:2025, WHO updated recommendations on HIV clinical management: recommendations for a public health approach
View latest version (2025)Bibliographic Info
GuidelineConsolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach
Year of Publication2016
Issuing InstitutionWHO
Recommendation
Status
Retired
Recommended in favor
Strong
Certainty of evidence
Low
After failure of a first-line regimen containing zidovudine (AZT) or stavudine (d4T) + lamivudine (3TC) or emtricitabine (FTC), the preferred nucleoside reverse transcriptase inhibitor (NRTI) backbone option for second-line ART is abacavir (ABC) or tenofovir disoproxil fumarate (TDF) + 3TC (or FTC)
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach
Year2013
InstitutionWHO